People with cancer and sarcoidosis worry about their old disease coming back when they start new immunotherapy. This analysis looked at 43 patients who had sarcoidosis before starting treatment. The goal was to see if their condition would flare up again. The good news is that 93 percent of these patients showed no signs of their sarcoidosis returning. Only 19.6 percent of the group experienced a flare. This means the vast majority stayed stable while fighting their cancer.
The type of drug mattered for some patients. Those taking anti-CTLA-4 inhibitors had a higher flare rate of 25 percent. Patients on anti-PD-1 or PD-L1 agents had a lower rate of 14.3 percent. Mixed regimens showed a rate of 3.1 percent. Even when a flare happened, the symptoms were usually mild to moderate. Very few cases required stopping the treatment permanently. No patient died from a flare or suffered irreversible damage.
However, the data has limits because there were so few patients. The numbers are small and should be treated as exploratory. We cannot say for sure if the drug causes the flare or if the flare happens by chance. This summary helps doctors understand the risks better, but more data is needed to be certain.